Amendment 30: DRIVe EZ Broad Agency Announcement

EZBAA-22-100-SOL-00003

Amendment #030

Office of Biomedical Advanced Research and Development Authority Division of Research, Innovation & Ventures (DRIVe)

Easy Broad Agency Announcement EZBAA-22-100-SOL-00003

The purpose of Amendment #030 is the following:
1) Add the following Area of Interest (AOI):
AOI #28: Influenza Vaccine Innovation
2) Pause the following Area of Interest (AOI):
AOI #26: Agnostic Diagnostic

EZBAA-22-100-SOL-00003

Amendment #030

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Adding the following research Area of Interest (AOI):
AOI #28: Influenza Vaccine Innovation

AOI #28: Influenza Vaccine Innovation
Influenza remains a serious health concern in the U.S. and globally, both as an annual disease (seasonal influenza) and as a threat for periodic outbreaks of widespread disease with higher rates of morbidity and mortality (pandemic influenza). There are three opportunities for vaccine intervention for pandemic influenza: during a public health emergency (PHE) in response to the emergence of a novel influenza virus, around the beginning of an influenza pandemic, and before a PHE has begun. Influenza vaccines are most effective when they induce neutralizing antibodies to the influenza virus strain causing disease. Less effective but still highly impactful to public health are pandemic influenza vaccines designed to be stockpiled and deployed at the beginning of a public health emergency. Since most of the U.S. population is vaccinated against seasonal influenza every year, an opportunity exists to confer partial immunity to influenza viruses with pandemic potential that could delay spread or potentially even prevent an influenza virus with pandemic potential from becoming a public health emergency.

The Influenza and Emerging Infectious Diseases Division (IEIDD) seeks innovations in influenza vaccines that could be deployed either before, around the beginning of, or during a PHE that are faster, more easily deployed, and/or more effective than currently available influenza vaccines. Currently there are two open sub-areas of focus for this topic, which may change over time.

EZBAA-22-100-SOL-00003

Amendment #030

Respondents may propose to any of the sub-areas individually or in combination, if appropriate. Subareas of focus include: X.1 Before a PHE Vaccine Innovations
X.1.1 Pandemic Protection on Day 1
Regardless of how much emergency vaccine capacity is established and sustained and how fast